Literature DB >> 8722048

Long-term glycemic control relates to mortality in type II diabetes.

D K Andersson1, K Svärdsudd.   

Abstract

OBJECTIVE: To study the influence of long-term glycemic control on mortality in a cohort of newly detected type II diabetic individuals. RESEARCH DESIGN AND METHODS: A total of 411 newly detected type II diabetic individuals diagnosed between 1972 and 1987 were followed until 31 December 1989. Clinical data concerning fasting blood glucose (FBG) values, body mass index (BMI), type of treatment, and concomitant diseases were collected during 8 randomly selected years. Long-term glycemic control was measured as annual averages of FBG values during these years. Mortality data were obtained from official registers.
RESULTS: There were 161 diabetic subjects who died during a mean follow-up time of 7.4 years. In univariate analyses, higher age at diagnosis; higher baseline or average FBG; and the presence of heart disease, cerebrovascular disease, or kidney disease at the beginning or during the course of diabetes were related to higher mortality. Type of diabetes treatment or having a diagnosis of hypertension was not related to mortality. In multiple logistic regression analyses, age at diagnosis and average FBG were independently related to all-cause (P = 0.0002), cardiovascular (P = 0.0006), and ischemic heart disease mortality (P = 0.03). No correlations between glycemic control and noncardiovascular deaths were found. In a Cox's regression analysis, average FBG was significantly related to length of survival when age at diabetes diagnosis was taken into account (P < 0.05). Diabetic subjects with average FBG > or = 7.8 mmol/l had 50% higher mortality compared with diabetic subjects with average FBG < 7.8 mmol/l.
CONCLUSIONS: Diabetic patients with good long-term glycemic control had a better survival rate than subjects with high average FBG values. The findings should be interpreted cautiously because possible confounding factors such as dyslipoproteinemia and smoking were not studied.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8722048     DOI: 10.2337/diacare.18.12.1534

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  19 in total

Review 1.  [New differential therapy of type 2 diabetes].

Authors:  M Schütt; H H Klein
Journal:  Internist (Berl)       Date:  2011-04       Impact factor: 0.743

2.  Overcoming social and cultural barriers to care for patients with diabetes.

Authors:  J Humphry; L M Jameson; S Beckham
Journal:  West J Med       Date:  1997-09

3.  PPAR-γ receptor agonists-a review of their role in diabetic management in Trinidad and Tobago.

Authors:  Steve Ian Smith
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

4.  Effect of trajectories of glycemic control on mortality in type 2 diabetes: a semiparametric joint modeling approach.

Authors:  Mulugeta Gebregziabher; Leonard E Egede; Cheryl P Lynch; Carrae Echols; Yumin Zhao
Journal:  Am J Epidemiol       Date:  2010-04-27       Impact factor: 4.897

Review 5.  Hyperglycemia and cardiovascular disease.

Authors:  W C Duckworth
Journal:  Curr Atheroscler Rep       Date:  2001-09       Impact factor: 5.113

6.  Diabetes outcomes in the Indian health system during the era of the Special Diabetes Program for Indians and the Government Performance and Results Act.

Authors:  Charlton Wilson; Susan Gilliland; Theresa Cullen; Kelly Moore; Yvette Roubideaux; Lorraine Valdez; William Vanderwagen; Kelly Acton
Journal:  Am J Public Health       Date:  2005-07-28       Impact factor: 9.308

7.  Hemoglobin A1c can be helpful in predicting progression to diabetes after Whipple procedure.

Authors:  Lisa Hamilton; D Rohan Jeyarajah
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

8.  Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor.

Authors:  A Ruigómez; L A García Rodríguez
Journal:  Eur J Epidemiol       Date:  1998-07       Impact factor: 8.082

9.  Impaired reduction of nocturnal systolic blood pressure and severity of diabetic retinopathy.

Authors:  João Soares Felício; Juliana Torres Pacheco; Sandra Roberta Ferreira; Frida Plavnik; Valdir Moisés; Oswaldo Kohlmann Junior; Artur Beltrame Ribeiro; Maria Tereza Zanella
Journal:  Exp Clin Cardiol       Date:  2007

10.  Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Authors:  Jorge Calles-Escandón; Laura C Lovato; Denise G Simons-Morton; David M Kendall; Rodica Pop-Busui; Robert M Cohen; Denise E Bonds; Vivian A Fonseca; Faramarz Ismail-Beigi; Mary Ann Banerji; Alan Failor; Bruce Hamilton
Journal:  Diabetes Care       Date:  2010-01-26       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.